Drug profile · INN
idelalisib
ZYDELIG
idelalisib (ZYDELIG) is a pi3-kinase p110-delta subunit inhibitor. Associated with Gilead Sciences Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Drug details — idelalisib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
idelalisib (ZYDELIG) is a pi3-kinase p110-delta subunit inhibitor. Associated with Gilead Sciences Pty Limited. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
PI3-kinase p110-delta subunit inhibitor
Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is idelalisib?
idelalisib (ZYDELIG) is a pi3-kinase p110-delta subunit inhibitor. Associated with Gilead Sciences Pty Limited. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for idelalisib?
ZYDELIG is a marketed brand name for idelalisib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of idelalisib?
idelalisib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.